Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics says double-digit revenue growth is sustainable

Allergy Therapeutics' (LON:AGY) chief executive officer Manuel Llobet talks to Proactive Investors UK about the company's "very strong" performance in the second half of 2015 as the group's products sales gain momentum in Europe.

Llobet points out the company gained market share across all its markets and for all the products in its portfolio and that the double-digit revenue growth seen over the period is sustainable throughout 2016.

 
Meet Acal Plc and Scancell Holdings Plc at our event, London, 07 July 2016. Register here »
View full AGY profile

Allergy Therapeutics plc Timeline

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.